Med LifeLTS:0RO5 75 Buyback Yield % is 0.01 as of Jul. 09, 2026, which is 75% below its 10-year median of 0.04. GuruFocus rates LTS:0RO5 with a GF Score™ of 75/100 and a GF Value™ of lei1.40 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 276 Healthcare Providers & Services companies, Med Life ranks better than 55.43% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Med Life's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RO5 vs HCA, THC, DVA: Buyback Yield % Comparison
For the Medical Care Facilities subindustry, Med Life's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Med Life's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life (LTS:0RO5) has a Buyback Yield % of 0.01 as of Jul. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Med Life and its competitors. This is 75% below median its historical median of 0.04. According to the industry distribution chart, Med Life ranks #123 out of 276 companies in the Healthcare Providers & Services industry, placing it in the top 44.6%.
Is Med Life's Buyback Yield % too high?
Med Life's current Buyback Yield % of 0.01 is 75% below median its 10-year median of 0.04. Based on the distribution chart, Med Life ranks #123 out of 276 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Med Life has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's Buyback Yield % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #123 out of 276 companies for Buyback Yield %. This puts Med Life in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Med Life and its competitors. Med Life's current Buyback Yield % is 0.01, which is 75% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.40, compared to a current price of lei11.38 — trading 712.5% above its estimated fair value. The current Buyback Yield % is 0.01, which is 75% below median its 10-year median of 0.04. Med Life's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current Buyback Yield % is 0.01 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.38 is trading 712.5% above its estimated GF Value™ of lei1.40.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
Buyback Yield %: 0.01 (75% below median its 10-year median of 0.04)
GF Value™: lei1.40 vs. price of lei11.38 (712.5% above fair value)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
75GF Score
Get the complete analysis for LTS:0RO5
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
